MGNXHealthcare · BiotechnologyThe 7 Wall Street analysts covering MacroGenics, Inc. hold a median 12-month price target of $8.5 — +139.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores MacroGenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MGNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +139.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | B. Riley Securities | Maintains | Buy | — |
| 17 Aug 2026 | B. Riley Securities | Maintains | Buy | $9.00 → $11 |
| 20 Apr 2026 | Barclays | Maintains | Overweight | — |
| 20 Apr 2026 | Barclays | Maintains | Overweight | $4.00 → $6.00 |
| 10 Apr 2026 | B. Riley Securities | Upgrade | Buy | — |
| 10 Mar 2026 | Barclays | Maintains | Overweight | — |
| 3 Nov 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 17 Sept 2025 | Barclays | Assumes | Overweight | $3.00 |
| 15 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
| 20 May 2025 | B. Riley Securities | Maintains | Neutral | — |
| 14 May 2025 | Barclays | Maintains | Overweight | — |
| 14 May 2025 | Stifel | Maintains | Hold | — |
| 25 Mar 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 7 Nov 2024 | JMP Securities | Downgrade | Market Perform | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | Citigroup | Maintains | Buy | — |
| 7 Aug 2024 | BMO Capital | Maintains | Market Perform | — |
| 1 Aug 2024 | BTIG | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGNX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, MacroGenics, Inc. returned +99.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 62% of US stocks
Cheaper than 18% of US stocks
Cheaper than 75% of US stocks
Higher than 97% of US stocks
Higher than 74% of US stocks
Higher than 67% of US stocks
Higher than 18% of US stocks
Higher than 21% of US stocks
Higher than 6% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MacroGenics, Inc. has a market value of $231.9M and an enterprise value of $94.0M.
Revenue in the twelve months to 30 June 2026: $167.7M. The latest quarter grew 378.0% year on year.
Net income over the same four quarters: −$14.6M, a −8.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$65.5M.
Trailing P/E: 25.3×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MacroGenics, Inc. employs 293 people — $572K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MacroGenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha introduced 38 new analysts for September 2026 and featured their top picks and investment strategies. Highlighted ideas included Qualcomm, Teladoc, NewLake Capital Partners, and the TDAQ ETF; MacroGenics was not mentioned.
Why it matters — The article provides no company-specific information about MacroGenics, so it offers no direct update for MGNX watchers.
MacroGenics announced that President and CEO Eric Risser will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 9:30 a.m. ET. The company focuses on developing antibody-based cancer therapies.
Why it matters — This participation gives MGNX watchers an opportunity to hear directly from the company's CEO regarding its oncology pipeline at a major investment conference.
Seeking Alpha highlighted MacroGenics as an inexpensive biotech trading at a discount to its $327 million cash position, with a differentiated pipeline spanning antibody drug conjugates, T-cell engagers, and lorigerlimab. The article notes multiple near-term catalysts and suggests the company's partnership potential is underappreciated given its negative enterprise value.
Why it matters — MGNX watchers would care because the article points to near-term pipeline catalysts and an underappreciated partnership opportunity that could influence the company's valuation.
The article compares MacroGenics (MGNX) and CareDx (CDNA) stock performance so far this year relative to their medical-sector peers. The headline poses the question of whether MGNX is outpacing its medical peers, addressing the stock's year-to-date performance within its sector.
Why it matters — MGNX watchers would care because the comparison indicates where the company's stock currently stands against its sector peers this year, signaling its relative performance in the market.
MacroGenics reported a Q2 loss of $0.27 per share, which was narrower than the Zacks Consensus Estimate of a $0.40 loss and improved from the $0.57 loss in the year-ago quarter. The company's quarterly results lagged revenue estimates.
Why it matters — MGNX watchers would note that the company's per-share loss narrowed significantly versus both analyst expectations and the prior-year quarter, even as revenue came up short of estimates.
The 7 Wall Street analysts covering MacroGenics, Inc. have a median 12-month price target of $8.5, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering MacroGenics, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MacroGenics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, MacroGenics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +139.4% from the last close, and Ticker Nerd's factor model ranks MacroGenics, Inc. 65 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MacroGenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.
MacroGenics, Inc. returned +99.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer.
The most recent item we track (Seeking Alpha, 7 Oct 2026): "Stock Picks From Seeking Alpha's September 2026 New Analysts". Seeking Alpha introduced 38 new analysts for September 2026 and featured their top picks and investment strategies. Highlighted ideas included Qualcomm, Teladoc, NewLake Capital Partners, and the TDAQ ETF; MacroGenics was not mentioned.
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.
CEO Mr. Eric Blasius Risser · 293 employees · United States · https://www.macrogenics.com
